| Hazard Information | Back Directory | [Uses]
Firivumab (CT-P22; CT120) is a human IgG1 monoclonal influenza A virus hemagglutinin (Anti-IAV HA) antibody. Firivumab is capable of neutralizing H1N1, H5N1, H6N1, H6N2, H8N4, H8N8, H9N2 and H12N7. Firivumab shows protection against H1N1 virus in mice[1][2][3]. | [in vivo]
Firivumab (CT-P22; CT120; 7.5-30 mg/kg; IP; Twenty-four hours post-infection) shows 100% protection against H1N1 virus in >15 mg/kg-treated group and 70% in 7.5 mg/kg-treated group[1].
CT-P27 (adding 7.5 mg/kg Firivumab and 7.5 mg/kg CT149) shows full protection in A/California/04/09 (H1N1)-treated mice[1].
| Animal Model: | Six- to nine-week-old female BALB/c mice with A/California/04/09 (H1N1) and A/Philippines/2/1982 (H3N2)[1] | | Dosage: | 7.5, 15, 30 mg/kg | | Administration: | IP; Twenty-four hours post-infection | | Result: | Showed 100% protection against H1N1 virus in >15 mg/kg-treated group and 70% in 7.5 mg/kg-treated group.
Could not protect mice from H3N2 infection. |
| [References]
[1] Kye Sook Yi, et al. Broader neutralization of CT-P27 against influenza A subtypes by combining two human monoclonal antibodies. PLoS One. 2020 Jul 29;15(7):e0236172. DOI:10.1371/journal.pone.0236172
[2] John H Beigel, et al. Influenza Therapeutics in Clinical Practice-Challenges and Recent Advances. Cold Spring Harb Perspect Med. 2021 Apr 1;11(4):a038463. DOI:10.1101/cshperspect.a038463
[3] Seung Suh Hong, et al. Composition comprising at least two influenza a virus-neutralizing-binding molecules. EP3011968A1. |
|
| Company Name: |
Biolab Reagents
|
| Tel: |
18108604356 18108604356 |
| Website: |
www.biolabreagent.com/ |
| Company Name: |
Cell Sciences
|
| Tel: |
9785721070 |
| Website: |
www.cellsciences.com |
|